Google Groups no longer supports new Usenet posts or subscriptions. Historical content remains viewable.
Dismiss
Drug researcher develops 'fat burning' molecule
1 view
Skip to first unread message
amin...@gmail.com
Jul 13, 2020, 2:55:28 PM7/13/20
to
Hello,
Drug researcher develops 'fat burning' molecule
Scientists have recently identified a small mitochondrial uncoupler, named BAM15, that decreases the body fat mass of mice without affecting food intake and muscle mass or increasing body temperature.
Webster Santos, professor of chemistry and his colleagues have recently identified a small mitochondrial uncoupler, named BAM15, that decreases the body fat mass of mice without affecting food intake and muscle mass or increasing body temperature. Additionally, the molecule decreases insulin resistance and has beneficial effects on oxidative stress and inflammation.
The findings, published in Nature Communications on May 14, 2020, hold promise for future treatment and prevention of obesity, diabetes, and especially nonalcoholic steatohepatitis (NASH), a type of fatty liver disease that is characterized by inflammation and fat accumulation in the liver. In the next few years, the condition is expected to become the leading cause of liver transplants in the United States.
Read more here:
https://www.sciencedaily.com/releases/2020/06/200608132539.htm
Thank you,
Amine Moulay Ramdane.
Drug researcher develops 'fat burning' molecule
Scientists have recently identified a small mitochondrial uncoupler, named BAM15, that decreases the body fat mass of mice without affecting food intake and muscle mass or increasing body temperature.
Webster Santos, professor of chemistry and his colleagues have recently identified a small mitochondrial uncoupler, named BAM15, that decreases the body fat mass of mice without affecting food intake and muscle mass or increasing body temperature. Additionally, the molecule decreases insulin resistance and has beneficial effects on oxidative stress and inflammation.
The findings, published in Nature Communications on May 14, 2020, hold promise for future treatment and prevention of obesity, diabetes, and especially nonalcoholic steatohepatitis (NASH), a type of fatty liver disease that is characterized by inflammation and fat accumulation in the liver. In the next few years, the condition is expected to become the leading cause of liver transplants in the United States.
Read more here:
https://www.sciencedaily.com/releases/2020/06/200608132539.htm
Thank you,
Amine Moulay Ramdane.
0 new messages